Movatterモバイル変換


[0]ホーム

URL:


US8298219B2 - Cryotreatment device using a supercritical gas - Google Patents

Cryotreatment device using a supercritical gas
Download PDF

Info

Publication number
US8298219B2
US8298219B2US12/552,399US55239909AUS8298219B2US 8298219 B2US8298219 B2US 8298219B2US 55239909 AUS55239909 AUS 55239909AUS 8298219 B2US8298219 B2US 8298219B2
Authority
US
United States
Prior art keywords
coolant
medical device
treatment region
phase
supercritical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active - Reinstated, expires
Application number
US12/552,399
Other versions
US20110054453A1 (en
Inventor
Jean-Pierre Lalonde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Cryocath LP
Original Assignee
Medtronic Cryocath LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Cryocath LPfiledCriticalMedtronic Cryocath LP
Priority to US12/552,399priorityCriticalpatent/US8298219B2/en
Assigned to MEDTRONIC CRYOCATH LPreassignmentMEDTRONIC CRYOCATH LPASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: LALONDE, JEAN-PIERRE
Priority to CA2772437Aprioritypatent/CA2772437C/en
Priority to CN201080039584.3Aprioritypatent/CN102596119B/en
Priority to PCT/CA2010/001251prioritypatent/WO2011026215A1/en
Priority to EP10813187.1Aprioritypatent/EP2467107B1/en
Publication of US20110054453A1publicationCriticalpatent/US20110054453A1/en
Application grantedgrantedCritical
Publication of US8298219B2publicationCriticalpatent/US8298219B2/en
Active - Reinstatedlegal-statusCriticalCurrent
Adjusted expirationlegal-statusCritical

Links

Images

Classifications

Definitions

Landscapes

Abstract

A method of cryogenically treating a tissue region is provided, including positioning a treatment region of a medical device proximate the tissue region; transferring coolant in a substantially liquid phase from a coolant reservoir to a subcooler; transitioning the coolant from the liquid phase into a supercritical state; transferring the supercritical coolant to the treatment region; changing the coolant from the supercritical state to at least one of a liquid phase and a gaseous phase at the treatment region; ablating the tissue region; and evacuating coolant from the treatment region of the medical device.

Description

CROSS-REFERENCE TO RELATED APPLICATION
n/a
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
n/a
FIELD OF THE INVENTION
The present invention relates to a coolant system and method of use for a cryogenic medical device.
BACKGROUND OF THE INVENTION
A number of cooled catheter systems have been developed for treating tissue in a cardiac setting, either to cool the tissue sufficiently to stun it and allow cold mapping of the heart and/or confirmation of catheter position with respect to localized tissue lesions, or to apply a more severe level of cold to ablate tissue at the site of the catheter ending. In general, the range of treatments which may be effected by a cryocatheter is comparable to the range of applications for radio frequency or thermal ablation catheters, and in particular, these instruments may be configured to achieve either small localized ball shape lesions at the tip of the catheter, or one or more elongated linear lesions extending a length of several centimeters or more along the tip. The latter form of lesion is commonly used to achieve conduction block across a region of the cardiac wall so as to sever an aberrant pathway over a length, preventing conduction across the region, in order change the cardiac signal path topology, for example, to eliminate a faulty pathway responsible for atrial fibrillation or a tachycardia.
A cryogenic device uses the energy transfer derived from thermodynamic changes occurring in the flow of a refrigerant through the device. Various fluids with low operating temperatures (such as cryogens or cryogenic refrigerants) have been used in the medical and surgical field to treat such tissue aberrations. In general, a cryogenic device uses the energy transfer derived from thermodynamic changes occurring in the flow of a cryogen therethrough to create a net transfer of heat flow from the target tissue to the device, typically achieved by cooling a portion of the device to very low temperature through conductive and convective heat transfer between the cryogen and target tissue. The quality and magnitude of heat transfer is regulated by the device configuration and control of the cryogen flow regime within the device.
Structurally, cooling can be achieved through injection of high pressure refrigerant through an orifice. Upon injection from the orifice, the refrigerant undergoes two primary thermodynamic changes: (i) expanding to low pressure and temperature through positive Joule-Thomson throttling, and (ii) undergoing a phase change from liquid to vapor, thereby absorbing heat of vaporization. The resultant flow of low temperature refrigerant through the device acts to absorb heat from the target tissue and thereby cool the tissue to the desired temperature.
A number of different fluids have been used for the coolant component of cryotreatment catheters, such as a concentrated saline solution or other liquid providing some degree of thermal conductivity and heat capacity. However, typical refrigerants and their respective refrigeration systems may be limited in their thermal conductivity and/or capacity to remove heat, either because of their particular thermal properties or because of insufficient temperature reduction prior to delivery of the refrigerant to a catheter.
To some extent these considerations have been addressed by using a phase change material as the cryogenic fluid, and arranging the catheter such that the phase change, e.g., from a liquid to a gas, occurs in the treatment portion of the catheter tip. Another possible approach is to employ a pressurized gas, and configure the catheter for cooling by expansion of the gas in the tip structure. However, owing to the small size that such a catheter is required to assume for vascular insertion, or the awkwardness of handling a cryogenic treatment probe generally, the design of a safe and effective coolant circulation system which nonetheless dependably provides sufficient cooling capacity at a remote tip and minimizes treatment times while increasing ablative lesion depth and quality remains a difficult goal.
Accordingly, it is desirable to provide a coolant system consistently, controllably delivering coolant to a treatment device with a cooling capacity that minimizes treatment time and improves the depth and quality of treatment.
SUMMARY OF THE INVENTION
The present invention advantageously provides a method and system for delivering coolant to a medical device and thermally treating a tissue region. In particular, a method of delivering coolant to a medical device is provided, including transferring a coolant in a supercritical state to a treatment region of the medical device; and changing the coolant from the supercritical state to at least one of a liquid phase and a gaseous phase at the treatment region. The method may include changing the coolant from the supercritical state to at least one of a liquid phase and a gaseous phase involving ejecting the coolant from a Joule-Thompson valve. The coolant may be changed from a supercritical state into a mixed liquid-gaseous state, and. transferring the coolant in a supercritical state to a treatment region of the medical device can include subcooling the coolant. The method may include drawing coolant from a reservoir in a liquid phase, and transitioning the coolant into a supercritical phase for delivery to the medical device, where transitioning the coolant into a supercritical phase for delivery to the medical device includes raising the pressure of the coolant with a pressure regulator. The method may also include monitoring a pressure level within the medical device and evacuating coolant from the medical device when the monitored pressure level varies from a predetermined target pressure.
A method of cryogenically treating a tissue region is also provided, including positioning a treatment region of a medical device proximate the tissue region; transferring coolant in a substantially liquid phase from a coolant reservoir to a subcooler; transitioning the coolant from the liquid phase into a supercritical state; transferring the supercritical coolant to the treatment region; changing the coolant from the supercritical state to at least one of a liquid phase and a gaseous phase at the treatment region; ablating the tissue region; and evacuating coolant from the treatment region of the medical device.
BRIEF DESCRIPTION OF THE DRAWINGS
A more complete understanding of the present invention, and the attendant advantages and features thereof, will be more readily understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:
FIG. 1 illustrates an embodiment of a medical system constructed in accordance with the principles of the present invention;
FIG. 2 illustrates an embodiment of a medical device constructed in accordance with the principles of the present invention;
FIG. 3 is a schematic representation of an embodiment of a cooling system constructed in accordance with the principles of the present invention;
FIG. 4 is another schematic representation of an embodiment of a cooling system constructed in accordance with the principles of the present invention;
FIG. 5 schematically represents an embodiment of a subcooler for the medical system according to the present invention;
FIG. 6 schematically represents another embodiment of a subcooler for the medical system according to the present invention;
FIG. 7 schematically represents an additional embodiment of a subcooler for the medical system according to the present invention;
FIG. 8 schematically represents still another embodiment of a subcooler for the medical system according to the present invention;
FIG. 9 schematically represents an additional embodiment of a subcooler for the medical system according to the present invention;
FIG. 10 schematically represents an embodiment of a subcooler for the medical system according to the present invention; and
FIG. 11 is a diagram illustrating phase relationship to pressure and temperature.
DETAILED DESCRIPTION OF THE INVENTION
The present invention includes a cryogenic cooling system and a medical device for use therewith. Referring now to the drawing figures in which like reference designations refer to like elements, an embodiment of a medical system constructed in accordance with principles of the present invention is shown inFIG. 1 and generally designated as “10.” The system generally includes a cooling unit orconsole12 coupled to amedical device14 through anumbilical system16. Themedical device14 may be a medical probe, a catheter, a balloon-catheter, as well as other devices deliverable or otherwise positionable through the vasculature and/or proximate to a tissue region for treatment. In particular, themedical device14 may include a device operable to thermally treat a selected tissue site, including cardiac tissue.
Umbilical system16 may include three separate umbilicals: a coaxial cable umbilical18, an electrical umbilical20 and a vacuum umbilical22. An outer vacuum umbilical may be suitable for a medical device having multiple layers or balloons. If the user wishes to perform a radiofrequency (“RF”) ablation procedure, radiofrequency energy can be provided to electrodes on themedical device14 via electrical umbilical20 to perform an RF ablation technique. Electrical umbilical20 can include an electrocardiograph (“ECG”) box24 to facilitate a connection from electrodes onmedical device14 to an ECG monitor (not shown). Coaxial umbilical18 may include both a cooling injection umbilical and a vacuum umbilical that provide respective inlet and return paths for a refrigerant or coolant used to cool a tissue-treating section of thedevice14. The vacuum umbilical22 may provide a safety conduit allowing excess coolant or gas to escape from thedevice14 if the pressure within themedical device14 exceeds a predefined limit. The vacuum umbilical22 can also be used to capture air through a leak of the outer vacuum system where it is outside the patient and as a lumen to ingress blood when inside the patient.
Now referring toFIG. 2, themedical device14 is shown in more detail. The medical device may include atreatment region26 for energy interaction between themedical device14 and a treatment site. Thetreatment region26 may include, for example, a balloon structure that can be a single wall or a double wall configuration. In a double-wall or dual-balloon configuration, the space or junction between balloon walls may be in communication with a vacuum source. In particular, the medical device may include ahandle28 having a number of proximal connector ports30a-30d.Port30amay be a first vacuum connector, having a first vacuum lumen therein, such as a 10French lumen. Port30bmay be a coaxial connector having both a vacuum lumen and injection therein, the vacuum lumen being a second vacuum lumen, such as an 8French lumen. Port30cmay be an electrical connector andport30dmay be a guidewire luer hub. Themedical device14 may include an elongate,flexible catheter body32 having aguidewire34 and aninner shaft36 andouter shaft38 having one or more lumens defined therethrough for the circulation and or deliver of a fluid or coolant to thetreatment region26 of themedical device14.
Thehandle28 may includeblood detection circuitry40 and apressure relief valve42. Thetreatment region26 of themedical device14 may include a first, inner expandable element (such as a balloon)44 and a second, outerexpandable element46 surrounding the firstexpandable element44.Radiopaque marker bands48 may be located proximate the exit point of coolant injected into thetreatment region26 to aid in the positioning and tracking of the device.
Themedical system10 may also include one or more sensors to monitor the operating parameters throughout the system, including for example, pressure, temperature, flow rates, volume, or the like in theconsole12, theumbilical system16, or themedical device14.
Now referring toFIG. 3, a schematic representation of theconsole12 for use with a medical device is shown. Theconsole12 includes various mechanical and/or electrical components to assist in the operation, control, and/or monitoring of themedical device14. Primarily, theconsole12 may be coupled to themedical device14 through theumbilical system16 to place afluid supply lumen50 and anexhaust lumen52 of theconsole12 in fluid communication with thetreatment region26 of themedical device14. In general, theconsole12 may further include afirst coolant reservoir54, asecond coolant reservoir56, and avacuum source58 As used herein, the term ‘reservoir’ is intended to include any container or chamber able to contain a fluid. As such, either of the first or second reservoirs may include a tank, container, or even a length of tubing or the like defining an interior space between two or more valves. Thesecond coolant reservoir56 may have a volumetric capacity smaller than the volumetric capacity of the first coolant reservoir54 (such as 20 cubic centimeters for example), which has been shown to reduce the likelihood of cardiac abnormalities and/or failure due to coolant egress into the vascular system. Thevacuum source58 may include any structure and/or apparatus able to provide a negative pressure gradient for providing fluid flow, including pumps, plunger devices, or the like.
One or more valves may be disposed about theconsole12 in fluid communication with thesupply lumen50 and/or theexhaust lumen52 for manipulating and/or providing fluid flow along a desired path. For example, theconsole12 may include a pair of valves,60 and62, in fluid communication with thefirst coolant reservoir54 such that thefirst coolant reservoir54 may be selectively switched from being in fluid communication with thesecond coolant reservoir56 to being in fluid communication with thesupply lumen50. Moreover, avalve64 may be disposed on theexhaust lumen52 such that theexhaust lumen52 may be selectively switched from being in fluid communication with thesecond coolant reservoir56 to being in fluid communication with thevacuum source58. In addition, theconsole12 may include one or more check valves and/or pressure relief valves CV configured to open to atmosphere or to a recovery tank should a pressure level and/or flow rate within a portion of theconsole100 exceed a desired or predetermined level. Such valves may further be operated to open portions of the system if so desired.
Theconsole12 may include avalve66 in fluid communication with both thesupply lumen50 and theexhaust lumen52. In particular, thevalve66 may be in fluid communication with thesupply lumen50 at a position upstream of the umbilical connector, while being in fluid communication with theexhaust lumen52 downstream from the umbilical connector. Thevalve66 may further be placed in fluid communication with the surrounding atmosphere to equalize pressure in both the exhaust and supply lumens. During operation, theconsole12 may detect a failure of themedical device14, such as an indication of the presence of blood or bodily fluid being entrained into the coolant system. Upon such detection, coolant flow may be terminated. However, despite the termination of coolant flow, due to the built-up pressure levels in the supply and exhaust lumens, bodily fluid may continue to be siphoned into the medical device and thus into portions of theconsole12. To reduce the likelihood that siphoning occurs, thevalve66 may be actuated to place both thesupply lumen50 and theexhaust lumen52 into fluid communication with the atmosphere. By doing so, the pressure in either lumen will be substantially equalized and thus will prevent the further ingress of bodily fluids into the medical device and thus the console. Of course, the equalization and/or subjection of both the supply and exhaust lumens may be achieved by using one or more valves in various configuration.
Theconsole12 may also include asubcooler68 disposed about a portion of thesupply lumen50 for achieving a desired temperature and/or coolant phase of fluid flowing therethrough. Thesubcooler68 may include a compressor, condenser and the like placed in thermal communication with thesupply lumen50 as previously discussed.
FIG. 5 discloses an example of a closed-loop subcooler in schematic form. As shown, the subcooler includes aheat exchange chamber70 having a coiledrefrigerant transfer line72 passing therethrough. Acompressor76 andcondenser78 provide liquid refrigerant that is transferred into thechamber70 as shown by the arrow marked “Ref. in.” The coolant, if compressed gas expands, or if liquid changes state to gas, thereby chilling thetransfer line72 and its contents. The expanded, gas-state coolant is exhausted from thechamber70 as shown by the arrow marked “Ref. out” and returned to thecompressor76; Acapillary tube80 can be interposed between thecondenser78 and thechamber70 in order to reduce the coolant flow into theheat exchanging chamber70.
Another example of asubcooler68 of the present system is shown inFIG. 6. The subcooler includes an insulated enclosure82 (like chamber70) encloses a coiled portion of acoolant supply line84 leading to a medical implement (not shown) as described above. Thecoolant supply line84 is in communication with acoolant reservoir86 to allow coolant to be directed into theenclosure82. Anoutlet88 in communication with avacuum source90 is provided to exhaust coolant from theenclosure82 whereupon it is directed to a scavenging system. Cooling performance can be controlled with acoolant flow regulator92 that can be made responsive to atemperature sensor94 within theenclosure82 that outputs a signal to atemperature controller96 that controls theflow regulator92.
Referring now toFIG. 7, an alternate subcooling configuration is shown.Chamber98 is depicted having anoutlet100. Provided within thechamber98 is aconduit102, having afirst end104 and asecond end106, defining a fluid flow path for a coolant or a refrigerant. Theconduit102 defines anaperture108. In practice, a refrigerant is supplied to thefirst end104 which then passes through the body of theconduit102 to thesecond end106. After the refrigerant enters theconduit102, a portion of the refrigerant is directed into thechamber98 via theaperture108. The refrigerant then expands to thereby cool thechamber98 and in turn theconduit102. The expanded refrigerant is then evacuated from thechamber98 via theoutlet100. The rate of flow through theaperture108 can be controlled by the size of the aperture as well as by flow control valves as discussed herein (not shown). The diameter of the aperture can range from 0.0001 to 0.03 inches, for example. The rate of subcooling affected within thechamber98 can be regulated by adjusting the flow rate of theoutlet100. By decreasing the flow rate allowed at theoutlet100, the amount of refrigerant entering thechamber98 via theaperture108 is thereby decreased and the subcooling reduced. Further, it is contemplated that the location of the aperture along theconduit102 can be varied.
Referring now toFIG. 8 which is a schematic view of another alternate embodiment of a subcooler illustrated in more detail. In the illustrated arrangement, refrigerant is supplied to the system from acoolant source110. The refrigerant passes through a filter or contaminant remover112 (optional) and then to ajunction114. One branch of the junction passes through avent system116 and the other branch passes throughsubcooler118. Thesubcooler118 chills the refrigerant to a temperature that causes the refrigerant to be in the liquid state prior to transfer to themedical device14. The illustrated arrangement permits placement of the subcooler within accessories external to the console, for example, in an connection box or intermediary console (not shown), in a catheter handle assembly or any other such device located between themedical device14 and theconsole12.
Referring now toFIG. 9, yet another configuration for a subcooler is illustrated in conjunction with a control system for the subcooler. As with configurations described above, this illustration depicts aheat exchange chamber120, having aninlet122 and anoutlet124, provides a flow path for refrigerant such as nitrous oxide or another fluid. Aconduit126 that defines a second fluid flow path for the same refrigerant passes through thechamber120 and is in fluid communication with a refrigerant supply upstream of the chamber and a medical device downstream from the chamber. As shown, afluid flow splitter128 can allow a common refrigerant source to be used for supplying thechamber120 and theconduit126.
Aprogrammable controller130 is in communication with and controls one or more valves, such as afirst valve132, to regulate flow of coolant through theconduit126 and into the medical device in response to a programmed cooling profile and in response to sensor outputs from the catheter. Additionally, thecontroller130 can be used to control asecond valve134 to regulate flow of coolant through thechamber120 in response to sensed temperature within the chamber. For example, thecontroller130 can establish a duty cycle that opens and closes thesecond valve134 repeatedly over time. If the temperature rises in thechamber120, thesecond valve134 can be opened and closed more frequently. By contrast, if the temperature in the chamber falls too far, thesecond valve134 can be cycled less frequently. Another example includes establishing a duty cycle to specifically regulate the temperature increases and decreases at the treatment site. It is advantageous to be able to precisely control the freezing and thawing rates of thetreatment region26 of themedical device14 when performing a medical treatment procedure. Further, by sensing the actual temperatures and adjusting the opening and closing of the system valves, the application of specific temperature regimens can be accomplished.
Referring now toFIG. 10, yet another configuration for a subcooler is illustrated in conjunction with a control system for the subcooler. The subcooler feature is provided by athermoelectric cooler136, such as a peltier cooler, the operation of which is known in the art. The thermo-electric cooler has ahot side138 and acold side140. Aconduit142 is provided adjacent and in thermally-conductive communication with thecold side140 of the thermo-electric cooler136. Asupplemental cooler144 is provided adjacent to and in thermally-conductive communication with thehot side138 of the thermoelectric cooler. Theconduit142, thethermoelectric cooler136 and thesupplemental cooler144 are enclosed by ahousing146. Thesupplemental cooler144 is connected to anexternal cooling source148 which can be any of the cooling arrangements disclosed herein or other such devices.
When the thermoelectric cooler is activated, the temperature of thecold side140 is reduced and thereby reduces the temperature of the adjacent conduit412, which in turn reduces the temperature of refrigerant passing through theconduit142. Further, thehot side138 increases in temperature. Thecooling source148 supplies cold energy to thesupplemental cooler144 which thereby cools the adjacenthot side138. By cooling thehot side138, heat is removed from thehousing146 and the cooling efficiency of thesupplemental cooler144 is increased. It is further contemplated that thehot side138 can be cooled by more conventional means such as moving air across it. Additionally, a heat sink can be provided in thermal communication with thehot side138 to increase cooling efficiency.
Again referring toFIG. 3, one or more sensors may be disposed about the supply and exhaust lumens of theconsole12 for detecting temperature, pressure, and/or flow rates through a particular portion of the console plumbing. For example, afirst pressure sensor150 may be disposed about theexhaust lumen52 proximate to the umbilical connector. In addition, asecond pressure sensor152 may be disposed about thesupply lumen50. Additional sensors SS may be included throughout theconsole12 for monitoring and/or controlling particular portions of the console and properties thereof.
In addition to the one or more sensors, one or more controllers may be coupled to the sensors, and in turn, coupled to one or more of the valves situated throughout theconsole12 such that the valves may be controllably manipulated in response to information obtained by the sensors. For example, afirst controller154 may be coupled to thefirst pressure sensor150, wherein thefirst controller154 is further coupled to avalve156 disposed on a portion of the exhaust line, and where thevalve156 may also be in fluid communication with thevacuum source58. In addition, asecond controller158 may be coupled to thesecond pressure sensor152, where thesecond controller158 is further coupled to avalve160 disposed about thesupply lumen50. Accordingly, fluid flow through portions of the exhaust and/or supply lumens may be controllably manipulated in direct response to the information obtained by sensors contained therein.
Now referring toFIG. 4, an embodiment of theconsole12, such as a cooling system for a cryogenic medical device, is shown. As shown, the console contains several of the valves, sensors and components discussed above with respect toFIG. 3. Theconsole12 further includes a bypasscoolant supply line162 extending from a junction betweenvalves62 and160. The bypasscoolant supply line162 includes abypass valve164, and rejoins thecoolant supply line50 on a distal side of thesubcooler68. The bypasscoolant supply line162 provides an avenue, conduit, or fluid pathway for delivery of coolant to the medical device without interacting or being exposed to the subcooler. The bypass may provide for the delivery of relatively warmer (or non-subcooled) coolant to themedical device14 to inflate it without cooling, or to thaw or otherwise increase the temperature of a portion of themedical device14, such as thetreatment region26.
In an exemplary use, theconsole12 may be operated to deliver a refrigerant or coolant in a supercritical state to themedical device14 for subsequent thermal treatment of selected tissue. A supercritical fluid is a substance at a temperature and pressure above its defined critical point. A critical point, also called a critical state, specifies the conditions (temperature, pressure and sometimes composition) at which a phase boundary ceases to exist. To reach or exceed a material's critical point, predetermined temperatures and pressure must be obtained. Critical properties vary from material to material, similar to melting points and boiling points.
As shown in the phase diagram ofFIG. 11, the supercritical phase of a substance lies beyond the liquid and gaseous phases—resulting in a fluid having characteristics of both. Supercritical fluids typically have gaseous characteristics (such as the ability to diffuse through solids) as well as liquid characteristics (such as the ability to dissolve materials). In the pressure-temperature phase diagram ofFIG. 11, boiling a material separates the gas and liquid region and ends in the critical point, where the liquid and gas phases disappear to become a single supercritical phase. As the critical temperature is approached, the density of the gas at equilibrium becomes denser, and that of the liquid lower. At the critical point, there is no difference in density, and the liquid and gaseous phases become one fluid phase. Thus, above the critical temperature a gas cannot be liquefied by pressure. A small increase in pressure causes a large increase in the density of the supercritical phase, allowing many properties of a supercritical fluid to be selectively and controllably manipulated. Many other physical properties also show large gradients with pressure near the critical point, e.g. viscosity, the relative permittivity and the solvent strength, which are all closely related to the density.
By delivering a supercritical fluid to thetreatment region26 of themedical device14, lower temperatures can be achieved through the expansion and/or evaporation of the coolant once delivered to the treatment region. The lower temperatures may be obtained by using a Joule-Thompson valve to obtain the desired expansion. The supercritical coolant has increased thermodynamic capacity for cooling upon expansion compared to a liquid or gaseous phase, resulting in lower thermal temperatures—which reduces the time needed for tissue ablation.
In an exemplary method of operation, a coolant or refrigerant having a pre-defined critical point may be supplied by or otherwise contained in thefirst coolant reservoir54. Exemplary coolants may include methane, argon, nitrogen, oxygen, krypton, and neon. The coolant in thefirst reservoir54 may be at a pressure and/or temperature combination such that the coolant is in a liquid phase, or in a mixed liquid-gaseous phase. Thefirst coolant reservoir54 may include a dip tube or other structure to ensure that only the liquid-phase coolant is drawn from thereservoir54 during use. The coolant may then proceed through the valves and conduits described above, which may direct the coolant through a subcooler prior to reaching themedical device14. The subcooler may operate to modify the temperature and pressure characteristics of the coolant to ensure the supercritical state of the coolant passing through thesupply lumen50. Once passing through the subcooler, the remaining lengths of conduit leading to thetreatment region26 of the medical device may include insulative properties to reduce thermal exchange with the surrounding environment. To further increase the stability of the supercritical state of the coolant, the dimensions of the fluid supply tube leading to and through the length of themedical device14 may be dimensioned to reduce the volume of coolant passing therethrough and to further maintain a desired pressure throughout the delivery path. Upon reaching the treatment region of themedical device14, the supercritical coolant may be dispersed through a valve or expansion element, thereby allowing at least a portion of the ejected coolant to change phase into a liquid, gas and/or combination thereof. The expansion into a gaseous phase and subsequent evaporation of the liquid phase coolant within thetreatment region26 provides increased cooling capacity and reduced temperatures for thermal ablation of a selected tissue region.
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described herein above. In addition, unless mention was made above to the contrary, it should be noted that all of the accompanying drawings are not to scale. A variety of modifications and variations are possible in light of the above teachings without departing from the scope and spirit of the invention, which is limited only by the following claims.

Claims (15)

US12/552,3992009-09-022009-09-02Cryotreatment device using a supercritical gasActive - Reinstated2031-02-21US8298219B2 (en)

Priority Applications (5)

Application NumberPriority DateFiling DateTitle
US12/552,399US8298219B2 (en)2009-09-022009-09-02Cryotreatment device using a supercritical gas
CA2772437ACA2772437C (en)2009-09-022010-08-16Cryotreatment device using a supercritical gas
CN201080039584.3ACN102596119B (en)2009-09-022010-08-16Cryotreatment device using a supercritical gas
PCT/CA2010/001251WO2011026215A1 (en)2009-09-022010-08-16Cryotreatment device using a supercritical gas
EP10813187.1AEP2467107B1 (en)2009-09-022010-08-16Cryotreatment device using a supercritical gas

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US12/552,399US8298219B2 (en)2009-09-022009-09-02Cryotreatment device using a supercritical gas

Publications (2)

Publication NumberPublication Date
US20110054453A1 US20110054453A1 (en)2011-03-03
US8298219B2true US8298219B2 (en)2012-10-30

Family

ID=43625940

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US12/552,399Active - Reinstated2031-02-21US8298219B2 (en)2009-09-022009-09-02Cryotreatment device using a supercritical gas

Country Status (5)

CountryLink
US (1)US8298219B2 (en)
EP (1)EP2467107B1 (en)
CN (1)CN102596119B (en)
CA (1)CA2772437C (en)
WO (1)WO2011026215A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20110208174A1 (en)*2010-02-232011-08-25Cpsi BiotechCryoclamp and method of use
US11331140B2 (en)2016-05-192022-05-17Aqua Heart, Inc.Heated vapor ablation systems and methods for treating cardiac conditions
US11589920B2 (en)2008-10-062023-02-28Santa Anna Tech LlcCatheter with a double balloon structure to generate and apply an ablative zone to tissue

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8298219B2 (en)*2009-09-022012-10-30Medtronic Cryocath LpCryotreatment device using a supercritical gas
ES2976564T3 (en)2011-02-012024-08-05Channel Medsystems Inc Apparatus for cryogenic treatment of a body cavity or lumen
WO2013013099A1 (en)*2011-07-192013-01-24Adagio Medical, Inc.Methods and devices for the treatment of atrial fibrillation
DK2766075T3 (en)2011-10-132021-10-18Mequ As INFUSION LIQUID HEATER
WO2013067421A2 (en)*2011-11-052013-05-10Medtronic Ardian Luxembourg S.A.R.L.Systems, devices and methods for crynogenic renal neuromodulation
AU2012393931B2 (en)2012-10-302018-07-05Nitro Medical LimitedApparatus, probe and method for a cryogenic system
US9381055B2 (en)*2013-03-132016-07-05Cryofocus Medtech (Shanghai) Co. Ltd.Therapeutic cryoablation system
US9072500B2 (en)2013-03-132015-07-07Thach DuongTherapeutic cryoablation system
ES2772728T3 (en)*2013-05-232020-07-08Channel Medsystems Inc Cryogenic treatment systems
US9468484B2 (en)*2013-09-132016-10-18Cryofocus Medtech (Shanghai) Co. Ltd.Automated balloon catheter fluid purging system
KR102300577B1 (en)2013-09-242021-09-08아다지오 메디컬, 인크.Endovascular near critical fluid based cryoablation catheter and related methods
EP3131487A4 (en)2014-04-172017-12-13Adagio Medical, Inc.Endovascular near critical fluid based cryoablation catheter having plurality of preformed treatment shapes
CN107205766B (en)2014-11-132020-04-14艾达吉欧医疗公司 Pressure-regulated cryoablation system and related methods
US10888671B2 (en)2015-08-142021-01-12Mequ A/SInfusion fluid warmer comprising printed circuit board heating elements
EP3349676A4 (en)2015-09-182019-05-15Adagio Medical, Inc. TISSUE CONTACT VERIFICATION SYSTEM
ITUB20154614A1 (en)*2015-10-132017-04-13Criotec Impianti S R L Device for the treatment of atrial fibrillation.
US10864031B2 (en)2015-11-302020-12-15Adagio Medical, Inc.Ablation method for creating elongate continuous lesions enclosing multiple vessel entries
US10788244B2 (en)*2016-02-012020-09-29Medtronic Cryocath LpRecovery system for N20
JP2020532408A (en)2017-09-052020-11-12アダージョ メディカル インコーポレイテッドAdagio Medical,Inc. Ablation catheter with shape memory stylet
US10993759B2 (en)*2017-10-202021-05-04Ethicon, Inc.Hypothermic linear surgical staplers and methods of use
CN109984836B (en)*2017-12-292022-03-04上海微创电生理医疗科技股份有限公司Cryoablation system
CN111836593B (en)2018-01-102024-12-17艾达吉欧医疗公司Cryoablation element with conductive liner
CN109431595B (en)*2019-01-282019-04-26上海导向医疗系统有限公司 Low temperature and high pressure resistant flexible cryoablation needle device
CN117100489B (en)*2023-10-242023-12-26成都科瑞普医疗器械有限公司A wound cold compress device for it is emergent

Citations (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CA2378054A1 (en)1999-06-252001-01-04Cryogen, Inc.Precooled cryogenic ablation system
US6575966B2 (en)*1999-08-232003-06-10Cryocath Technologies Inc.Endovascular cryotreatment catheter
US6592577B2 (en)*1999-01-252003-07-15Cryocath Technologies Inc.Cooling system
US7083612B2 (en)*2003-01-152006-08-01Cryodynamics, LlcCryotherapy system
US7273479B2 (en)*2003-01-152007-09-25Cryodynamics, LlcMethods and systems for cryogenic cooling
US7310955B2 (en)*2004-09-032007-12-25Nitrocision LlcSystem and method for delivering cryogenic fluid
US20100057067A1 (en)2008-09-032010-03-04Baust John MModular pulsed pressure device for the transport of liquid cryogen to a cryoprobe
US20110054453A1 (en)*2009-09-022011-03-03Jean-Pierre LalondeCryotreatment device using a supercritical gas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6635053B1 (en)*1999-01-252003-10-21Cryocath Technologies Inc.Cooling system
JP4150825B2 (en)2003-03-312008-09-17独立行政法人理化学研究所 NMR probe
CN1935096A (en)*2005-09-222007-03-28上海导向医疗系统有限公司Nitrogen precooled throttling tumour ultra low temperature therapeutical system

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6592577B2 (en)*1999-01-252003-07-15Cryocath Technologies Inc.Cooling system
CA2378054A1 (en)1999-06-252001-01-04Cryogen, Inc.Precooled cryogenic ablation system
US6575966B2 (en)*1999-08-232003-06-10Cryocath Technologies Inc.Endovascular cryotreatment catheter
US7083612B2 (en)*2003-01-152006-08-01Cryodynamics, LlcCryotherapy system
US7273479B2 (en)*2003-01-152007-09-25Cryodynamics, LlcMethods and systems for cryogenic cooling
US20080173028A1 (en)2003-01-152008-07-24Cryodynamics, LlcMethods and systems for cryogenic cooling
US7310955B2 (en)*2004-09-032007-12-25Nitrocision LlcSystem and method for delivering cryogenic fluid
US20100057067A1 (en)2008-09-032010-03-04Baust John MModular pulsed pressure device for the transport of liquid cryogen to a cryoprobe
US20110054453A1 (en)*2009-09-022011-03-03Jean-Pierre LalondeCryotreatment device using a supercritical gas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Supercritical Fluid, Wikipedia, Jan. 20, 2010, http://en.wikipedia.org/wiki/Supercritical-fluid.
Supercritical Fluid, Wikipedia, Jan. 20, 2010, http://en.wikipedia.org/wiki/Supercritical—fluid.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US11589920B2 (en)2008-10-062023-02-28Santa Anna Tech LlcCatheter with a double balloon structure to generate and apply an ablative zone to tissue
US20110208174A1 (en)*2010-02-232011-08-25Cpsi BiotechCryoclamp and method of use
US11331140B2 (en)2016-05-192022-05-17Aqua Heart, Inc.Heated vapor ablation systems and methods for treating cardiac conditions
US12137969B2 (en)2016-05-192024-11-12Aqua Heart, Inc.Heated vapor ablation systems and methods for treating cardiac conditions

Also Published As

Publication numberPublication date
CA2772437A1 (en)2011-03-10
EP2467107A1 (en)2012-06-27
EP2467107B1 (en)2021-03-24
CN102596119B (en)2014-10-22
CN102596119A (en)2012-07-18
EP2467107A4 (en)2017-08-02
US20110054453A1 (en)2011-03-03
WO2011026215A1 (en)2011-03-10
CA2772437C (en)2014-12-02

Similar Documents

PublicationPublication DateTitle
US8298219B2 (en)Cryotreatment device using a supercritical gas
US11357563B2 (en)Method and apparatus for inflating and deflating balloon catheters
EP1357847B1 (en)Pre-cooled cryogenic medical system
US8491636B2 (en)Method and apparatus for inflating and deflating balloon catheters
CA2965314C (en)Pressure modulated cryoablation system and related methods
US9555223B2 (en)Method and apparatus for inflating and deflating balloon catheters
US7442190B2 (en)Contact assessment of balloon catheters
EP2704653B1 (en)Adiabatic cooling system for medical devices

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:MEDTRONIC CRYOCATH LP, CANADA

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LALONDE, JEAN-PIERRE;REEL/FRAME:023612/0985

Effective date:20091002

FEPPFee payment procedure

Free format text:PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

ZAAANotice of allowance and fees due

Free format text:ORIGINAL CODE: NOA

ZAABNotice of allowance mailed

Free format text:ORIGINAL CODE: MN/=.

STCFInformation on status: patent grant

Free format text:PATENTED CASE

FPAYFee payment

Year of fee payment:4

MAFPMaintenance fee payment

Free format text:PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment:8

FEPPFee payment procedure

Free format text:MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPSLapse for failure to pay maintenance fees

Free format text:PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCHInformation on status: patent discontinuation

Free format text:PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FPLapsed due to failure to pay maintenance fee

Effective date:20241030

FEPPFee payment procedure

Free format text:SURCHARGE, PETITION TO ACCEPT PYMT AFTER EXP, UNINTENTIONAL (ORIGINAL EVENT CODE: M1558); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text:PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFPMaintenance fee payment

Free format text:PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment:12

FEPPFee payment procedure

Free format text:PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY


[8]ページ先頭

©2009-2025 Movatter.jp